|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Vincent-Salomon A and Thiery JP: Host
microenvironment in breast cancer development:
epithelial-mesenchymal transition in breast cancer development.
Breast Cancer Res. 5:101–106. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Middleton LP, Tressera F, Sobel ME, Bryant
BR, Alburquerque A, Grases P and Merino MJ: Infiltrating
micropapillary carcinoma of the breast. Mod Pathol. 12:499–504.
1999.PubMed/NCBI
|
|
4
|
Goldstein NS, Vicini FA, Kestin LL and
Thomas M: Differences in the pathologic features of ductal
carcinoma in situ of the breast based on patient age. Cancer.
88:2553–2560. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li CI, Anderson BO, Porter P, Holt SK,
Daling JR and Moe RE: Changing incidence rate of invasive lobular
breast carcinoma among older women. Cancer. 88:2561–2569. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lakhani SR, Audretsch W, Cleton-Jensen AM,
Cutuli B, Ellis I, Eusebi V, Greco M, Houslton RS, Kuhl CK, Kurtz
J, et al: The management of lobular carcinoma in situ (LCIS). Is
LCIS the same as ductal carcinoma in situ (DCIS)? Eur J Cancer.
42:2205–2211. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cianfrocca M and Goldstein LJ: Prognostic
and predictive factors in early-stage breast cancer. Oncologist.
9:606–616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lehman CD, Gatsonis C, Kuhl CK, Hendrick
RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB,
et al: MRI evaluation of the contralateral breast in women with
recently diagnosed breast cancer. N Engl J Med. 356:1295–1303.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Skinner KA and Silverstein MJ: The
management of ductal carcinoma in situ of the breast. Endocr Relat
Cancer. 8:33–45. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singletary SE and Connolly JL: Breast
cancer staging: working with the sixth edition of the AJCC Cancer
Staging Manual. CA Cancer J Clin. 56:37–50. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Askoxylakis V, Thieke C, Pleger ST, Most
P, Tanner J, Lindel K, Katus HA, Debus J and Bischof M: Long-term
survival of cancer patients compared to heart failure and stroke: a
systematic review. BMC Cancer. 10:1052010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lv H, Pan G, Zheng G, Wu X, Ren H, Liu Y
and Wen J: Expression and functions of the repressor element 1
(RE-1)-silencing transcription factor (REST) in breast cancer. J
Cell Biochem. 110:968–974. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vogel KJ, Atchley DP, Erlichman J, Broglio
KR, Ready KJ, Valero V, Amos CI, Hortobagyi GN, Lu KH and Arun B:
BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation
prevalence and evaluation of the BRCAPRO risk assessment model. J
Clin Oncol. 25:4635–4641. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Olsson H: Tumour biology of a breast
cancer at least partly reflects the biology of the
tissue/epithelial cell of origin at the time of initiation - a
hypothesis. J Steroid Biochem Mol Biol. 74:345–350. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giordano SH, Cohen DS, Buzdar AU, Perkins
G and Hortobagyi GN: Breast carcinoma in men: a population-based
study. Cancer. 101:51–57. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iredale R, Brain K, Williams B, France E
and Gray J: The experiences of men with breast cancer in the United
Kingdom. Eur J Cancer. 42:334–341. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yager JD and Davidson NE: Estrogen
carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nass SJ and Davidson NE: The biology of
breast cancer. Hematol Oncol Clin North Am. 13:311–332. 1999.
View Article : Google Scholar
|
|
19
|
Antonova L, Aronson K and Mueller CR:
Stress and breast cancer: from epidemiology to molecular biology.
Breast Cancer Res. 13:2082010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McTiernan A: Behavioral risk factors in
breast cancer: can risk be modified? Oncologist. 8:326–334. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Friedenreich CM, Courneya KS and Bryant
HE: Influence of physical activity in different age and life
periods on the risk of breast cancer. Epidemiology. 12:604–612.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
MacConaill LE, Campbell CD, Kehoe SM, Bass
AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, et al:
Profiling critical cancer gene mutations in clinical tumor samples.
PLoS One. 4:e78872009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Martin AM and Weber BL: Genetic and
hormonal risk factors in breast cancer. J Natl Cancer Inst.
92:1126–1135. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Plak K, Czarnecka AM, Krawczyk T, Golik P
and Bartnik E: Breast cancer as a mitochondrial disorder (Review).
Oncol Rep. 21:845–851. 2009.PubMed/NCBI
|
|
25
|
Lynch HT, Silva E, Snyder C and Lynch JF:
Hereditary breast cancer: part I. Diagnosing hereditary breast
cancer syndromes. Breast J. 14:3–13. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Singletary SE: Rating the risk factors for
breast cancer. Ann Surg. 237:474–482. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kadouri L, Hubert A, Rotenberg Y,
Hamburger T, Sagi M, Nechushtan C, Abeliovich D and Peretz T:
Cancer risks in carriers of the BRCA1/2 Ashkenazi founder
mutations. J Med Genet. 44:467–471. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Campeau PM, Foulkes WD and Tischkowitz MD:
Hereditary breast cancer: new genetic developments, new therapeutic
avenues. Hum Genet. 124:31–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
King MC, Marks JH and Mandell JB: Breast
and ovarian cancer risks due to inherited mutations in BRCA1 and
BRCA2. Science. 302:643–646. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thorslund T and West SC: BRCA2: a
universal recombinase regulator. Oncogene. 26:7720–7730. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Welcsh PL and King MC: BRCA1 and BRCA2 and
the genetics of breast and ovarian cancer. Hum Mol Genet.
10:705–713. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Narod SA and Foulkes WD: BRCA1 and BRCA2:
1994 and beyond. Nat Rev Cancer. 4:665–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thorslund T, Esashi F and West SC:
Interactions between human BRCA2 protein and the meiosis-specific
recombinase DMC1. EMBO J. 26:2915–2922. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Verhoog LC, Berns EM, Brekelmans CT,
Seynaeve C, Meijers-Heijboer EJ and Klijn JG: Prognostic
significance of germline BRCA2 mutations in hereditary breast
cancer patients. J Clin Oncol. 18:119S–124S. 2000.PubMed/NCBI
|
|
35
|
Loman N, Johannsson O, Bendahl P, Dahl N,
Einbeigi Z, Gerdes A, Borg A and Olsson H: Prognosis and clinical
presentation of BRCA2-associated breast cancer. Eur J Cancer.
36:1365–1373. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lim LY, Vidnovic N, Ellisen LW and Leong
CO: Mutant p53 mediates survival of breast cancer cells. Br J
Cancer. 101:1606–1612. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bergamaschi D, Gasco M, Hiller L, Sullivan
A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, et
al: p53 polymorphism influences response in cancer chemotherapy via
modulation of p73-dependent apoptosis. Cancer Cell. 3:387–402.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Geisler S, Lonning PE, Aas T, Johnsen H,
Fluge O, Haugen DF, Lillehaug JR, Akslen LA and Borresen-Dale AL:
Influence of TP53 gene alterations and c-erbB-2 expression on the
response to treatment with doxorubicin in locally advanced breast
cancer. Cancer Res. 61:2505–2512. 2001.PubMed/NCBI
|
|
39
|
Beroud C and Soussi T: p53 gene mutation:
software and database. Nucleic Acids Res. 26:200–204. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vousden KH and Lane DP: p53 in health and
disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar
|
|
41
|
Olivier M, Petitjean A, Marcel V, Petre A,
Mounawar M, Plymoth A, de Fromentel CC and Hainaut P: Recent
advances in p53 research: an interdisciplinary perspective. Cancer
Gene Ther. 16:1–12. 2009. View Article : Google Scholar
|
|
42
|
Hohenstein P and Giles RH: BRCA1: a
scaffold for p53 response? Trends Genet. 19:489–494. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Coutant C, Rouzier R, Qi Y, Lehmann-Che J,
Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F,
de The H and Pusztai L: Distinct p53 gene signatures are needed to
predict prognosis and response to chemotherapy in ER-positive and
ER-negative breast cancers. Clin Cancer Res. 17:2591–2601. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yamashita H, Nishio M, Toyama T, Sugiura
H, Zhang Z, Kobayashi S and Iwase H: Coexistence of HER2
over-expression and p53 protein accumulation is a strong prognostic
molecular marker in breast cancer. Breast Cancer Res. 6:R24–30.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
45
|
Feki A and Irminger-Finger I: Mutational
spectrum of p53 mutations in primary breast and ovarian tumors.
Crit Rev Oncol Hematol. 52:103–116. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang J, Ren Y, Wang L, Li B, Chen Y, Zhao
W, Xu W, Li T and Dai F: PTEN mutation spectrum in breast cancers
and breast hyperplasia. J Cancer Res Clin Oncol. 136:1303–1311.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wallace JA, Li F, Leone G and Ostrowski
MC: Pten in the breast tumor microenvironment: modeling
tumor-stroma coevolution. Cancer Res. 71:1203–1207. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tokunaga E, Oki E, Kimura Y, Yamanaka T,
Egashira A, Nishida K, Koga T, Morita M, Kakeji Y and Maehara Y:
Coexistence of the loss of heterozygosity at the PTEN locus and
HER2 overexpression enhances the Akt activity thus leading to a
negative progesterone receptor expression in breast carcinoma.
Breast Cancer Res Treat. 101:249–257. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Marty B, Maire V, Gravier E, Rigaill G,
Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdes A,
Gestraud P, et al: Frequent PTEN genomic alterations and activated
phosphatidylinositol 3-kinase pathway in basal-like breast cancer
cells. Breast Cancer Res. 10:R1012008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
DeGraffenried LA, Fulcher L, Friedrichs
WE, Grunwald V, Ray RB and Hidalgo M: Reduced PTEN expression in
breast cancer cells confers susceptibility to inhibitors of the PI3
kinase/Akt pathway. Ann Oncol. 15:1510–1516. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tate G, Suzuki T and Mitsuya T: Mutation
of the PTEN gene in a human hepatic angiosarcoma. Cancer Genet
Cytogenet. 178:160–162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Petrocelli T and Slingerland JM: PTEN
deficiency: a role in mammary carcinogenesis. Breast Cancer Res.
3:356–360. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lee JS, Kim HS, Kim YB, Lee MC, Park CS
and Min KW: Reduced PTEN expression is associated with poor outcome
and angiogenesis in invasive ductal carcinoma of the breast. Appl
Immunohistochem Mol Morphol. 12:205–210. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Steelman LS, Navolanic PM, Sokolosky ML,
Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman
KM, Terrian DM, et al: Suppression of PTEN function increases
breast cancer chemotherapeutic drug resistance while conferring
sensitivity to mTOR inhibitors. Oncogene. 27:4086–4095. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tanaka M, Koul D, Davies MA, Liebert M,
Steck PA and Grossman HB: MMAC1/PTEN inhibits cell growth and
induces chemosensitivity to doxorubicin in human bladder cancer
cells. Oncogene. 19:5406–5412. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bates RC, Edwards NS, Burns GF and Fisher
DE: A CD44 survival pathway triggers chemoresistance via lyn kinase
and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer
Res. 61:5275–5283. 2001.PubMed/NCBI
|
|
58
|
Nevanlinna H and Bartek J: The CHEK2 gene
and inherited breast cancer susceptibility. Oncogene. 25:5912–5919.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Shaag A, Walsh T, Renbaum P, Kirchhoff T,
Nafa K, Shiovitz S, Mandell JB, Welcsh P, Lee MK, Ellis N, et al:
Functional and genomic approaches reveal an ancient CHEK2 allele
associated with breast cancer in the Ashkenazi Jewish population.
Hum Mol Genet. 14:555–563. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Abraham RT: PI 3-kinase related kinases:
‘big’ players in stress-induced signaling pathways. DNA Repair.
3:883–887. 2004.
|
|
61
|
Angele S, Romestaing P, Moullan N,
Vuillaume M, Chapot B, Friesen M, Jongmans W, Cox DG, Pisani P,
Gerard JP and Hall J: ATM haplotypes and cellular response to DNA
damage: association with breast cancer risk and clinical
radiosensitivity. Cancer Res. 63:8717–8725. 2003.PubMed/NCBI
|
|
62
|
McKinnon PJ: ATM and ataxia
telangiectasia. EMBO Rep. 5:772–776. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Milne RL: Variants in the ATM gene and
breast cancer susceptibility. Genome Med. 1:122009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lee JH and Paull TT: Direct activation of
the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science.
304:93–96. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Consortium TCBCC-C: CHEK2*1100delC and
susceptibility to breast cancer: a collaborative analysis involving
10,860 breast cancer cases and 9,065 controls from 10 studies. Am J
Hum Genet. 74:1175–1182. 2004.
|
|
66
|
Kilpivaara O, Vahteristo P, Falck J,
Syrjakoski K, Eerola H, Easton D, Bartkova J, Lukas J, Heikkila P,
Aittomaki K, et al: CHEK2 variant I157T may be associated with
increased breast cancer risk. Int J Cancer. 111:543–547. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kleibl Z, Havranek O, Novotny J, Kleiblova
P, Soucek P and Pohlreich P: Analysis of CHEK2 FHA domain in Czech
patients with sporadic breast cancer revealed distinct rare genetic
alterations. Breast Cancer Res Treat. 112:159–164. 2008. View Article : Google Scholar
|
|
68
|
Le GM, O’Malley CD, Glaser SL, Lynch CF,
Stanford JL, Keegan TH and West DW: Breast implants following
mastectomy in women with early-stage breast cancer: prevalence and
impact on survival. Breast Cancer Res. 7:R184–193. 2005.PubMed/NCBI
|
|
69
|
Brown SL: Epidemiology of silicone-gel
breast implants. Epidemiology. 13:S34–39. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Bese NS, Kiel K, El-Gueddari Bel K,
Campbell OB, Awuah B and Vikram B: Radiotherapy for breast cancer
in countries with limited resources: program implementation and
evidence-based recommendations. Breast J. 12:S96–102.
2006.PubMed/NCBI
|
|
71
|
Goss PE, Ingle JN, Martino S, Robert NJ,
Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard
KI, et al: Randomized trial of letrozole following tamoxifen as
extended adjuvant therapy in receptor-positive breast cancer:
updated findings from NCIC CTG MA.17. J Natl Cancer Inst.
97:1262–1271. 2005. View Article : Google Scholar
|
|
72
|
Crew KD, Greenlee H, Capodice J, Raptis G,
Brafman L, Fuentes D, Sierra A and Hershman DL: Prevalence of joint
symptoms in postmenopausal women taking aromatase inhibitors for
early-stage breast cancer. J Clin Oncol. 25:3877–3883. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zoli W, Ulivi P, Tesei A, Fabbri F,
Rosetti M, Maltoni R, Giunchi DC, Ricotti L, Brigliadori G, Vannini
I and Amadori D: Addition of 5-fluorouracil to
doxorubicin-paclitaxel sequence increases caspase-dependent
apoptosis in breast cancer cell lines. Breast Cancer Res.
7:R681–689. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
McArthur HL, Mahoney KM, Morris PG, Patil
S, Jacks LM, Howard J, Norton L and Hudis CA: Adjuvant trastuzumab
with chemotherapy is effective in women with small, node-negative,
HER2-positive breast cancer. Cancer. 117:5461–5468. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Piccart M: The role of taxanes in the
adjuvant treatment of early stage breast cancer. Breast Cancer Res
Treat. 79(Suppl 1): S25–34. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Weiss RB, Woolf SH, Demakos E, Holland JF,
Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson
IC and Norton L: Natural history of more than 20 years of
node-positive primary breast carcinoma treated with
cyclophosphamide, methotrexate, and fluorouracil-based adjuvant
chemotherapy: a study by the Cancer and Leukemia Group B. J Clin
Oncol. 21:1825–1835. 2003.
|
|
77
|
Hedley D, Ogilvie L and Springer C:
Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a
new weapon in the GDEPT armoury. Nat Rev Cancer. 7:870–879. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Nawa A, Tanino T, Luo C, Iwaki M, Kajiyama
H, Shibata K, Yamamoto E, Ino K, Nishiyama Y and Kikkawa F: Gene
directed enzyme prodrug therapy for ovarian cancer: could GDEPT
become a promising treatment against ovarian cancer? Anticancer
Agents Med Chem. 8:232–239. 2008. View Article : Google Scholar
|
|
79
|
Greco O and Dachs GU: Gene directed
enzyme/prodrug therapy of cancer: historical appraisal and future
prospectives. J Cell Physiol. 187:22–36. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
McKeown SR, Ward C and Robson T:
Gene-directed enzyme prodrug therapy: a current assessment. Curr
Opin Mol Ther. 6:421–435. 2004.PubMed/NCBI
|
|
81
|
Voeks D, Martiniello-Wilks R, Madden V,
Smith K, Bennetts E, Both GW and Russell PJ: Gene therapy for
prostate cancer delivered by ovine adenovirus and mediated by
purine nucleoside phosphorylase and fludarabine in mouse models.
Gene Ther. 9:759–768. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Anderson WF: Gene therapy scores against
cancer. Nat Med. 6:862–863. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chung-Faye GA, Kerr DJ, Young LS and
Searle PF: Gene therapy strategies for colon cancer. Mol Med Today.
6:82–87. 2000. View Article : Google Scholar
|
|
84
|
Schepelmann S, Hallenbeck P, Ogilvie LM,
Hedley D, Friedlos F, Martin J, Scanlon I, Hay C, Hawkins LK,
Marais R and Springer CJ: Systemic gene-directed enzyme prodrug
therapy of hepatocellular carcinoma using a targeted adenovirus
armed with carboxypeptidase G2. Cancer Res. 65:5003–5008. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Chung-Faye GA, Chen MJ, Green NK, Burton
A, Anderson D, Mautner V, Searle PF and Kerr DJ: In vivo gene
therapy for colon cancer using adenovirus-mediated, transfer of the
fusion gene cytosine deaminase and uracil
phosphoribosyltransferase. Gene Ther. 8:1547–1554. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Hernandez-Alcoceba R, Sangro B and Prieto
J: Gene therapy of liver cancer. World J Gastroenterol.
12:6085–6097. 2006.
|
|
87
|
Yi BR, O SN, Kang NH, Hwang KA, Kim SU,
Jeung EB, Kim YB, Heo GJ and Choi KC: Genetically engineered stem
cells expressing cytosine deaminase and interferon-β migrate to
human lung cancer cells and have potentially therapeutic anti-tumor
effects. Int J Oncol. 39:833–839. 2011.
|
|
88
|
Yi BR, Kang NH, Hwang KA, Kim SU, Jeung EB
and Choi KC: Antitumor therapeutic effects of cytosine deaminase
and interferon-β against endometrial cancer cells using genetically
engineered stem cells in vitro. Anticancer Res. 31:2853–2861.
2011.
|
|
89
|
Dachs GU, Hunt MA, Syddall S, Singleton DC
and Patterson AV: Bystander or no bystander for gene directed
enzyme prodrug therapy. Molecules. 14:4517–4545. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Pfeifer A and Verma IM: Gene therapy:
promises and problems. Annu Rev Genomics Hum Genet. 2:177–211.
2001. View Article : Google Scholar
|
|
91
|
Shah K: Mesenchymal stem cells engineered
for cancer therapy. Adv Drug Deliv Rev. 64:739–748. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Ramnaraine M, Pan W, Goblirsch M, Lynch C,
Lewis V, Orchard P, Mantyh P and Clohisy DR: Direct and bystander
killing of sarcomas by novel cytosine deaminase fusion gene. Cancer
Res. 63:6847–6854. 2003.PubMed/NCBI
|
|
93
|
Nyati MK, Symon Z, Kievit E, Dornfeld KJ,
Rynkiewicz SD, Ross BD, Rehemtulla A and Lawrence TS: The potential
of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy
in an intrahepatic colon cancer model. Gene Ther. 9:844–849.
2002.PubMed/NCBI
|
|
94
|
Ireton GC, Black ME and Stoddard BL:
Crystallization and preliminary X-ray analysis of bacterial
cytosine deaminase. Acta Crystallogr D Biol Crystallogr.
57:1643–1645. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Ireton GC, Black ME and Stoddard BL: The
1.14 A crystal structure of yeast cytosine deaminase: evolution of
nucleotide salvage enzymes and implications for genetic
chemotherapy. Structure. 11:961–972. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Denny WA: Prodrugs for Gene-Directed
Enzyme-Prodrug Therapy (Suicide Gene Therapy). J Biomed Biotechnol.
2003:48–70. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Ireton GC, McDermott G, Black ME and
Stoddard BL: The structure of Escherichia coli cytosine deaminase.
J Mol Biol. 315:687–697. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Fuchita M, Ardiani A, Zhao L, Serve K,
Stoddard BL and Black ME: Bacterial cytosine deaminase mutants
created by molecular engineering show improved
5-fluorocytosine-mediated cell killing in vitro and in vivo. Cancer
Res. 69:4791–4799. 2009. View Article : Google Scholar
|
|
99
|
Kim KY, Kim SU, Leung PC, Jeung EB and
Choi KC: Influence of the prodrugs 5-fluorocytosine and CPT-11 on
ovarian cancer cells using genetically engineered stem cells:
tumor-tropic potential and inhibition of ovarian cancer cell
growth. Cancer Sci. 101:955–962. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Chen JK, Hu LJ, Wang D, Lamborn KR and
Deen DF: Cytosine deaminase/5-fluorocytosine exposure induces
bystander and radiosensitization effects in hypoxic glioblastoma
cells in vitro. Int J Radiat Oncol Biol Phys. 67:1538–1547. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Miller CR, Williams CR, Buchsbaum DJ and
Gillespie GY: Intratumoral 5-fluorouracil produced by cytosine
deaminase/5-fluorocytosine gene therapy is effective for
experimental human glioblastomas. Cancer Res. 62:773–780.
2002.PubMed/NCBI
|
|
102
|
Humerickhouse R, Lohrbach K, Li L, Bosron
WF and Dolan ME: Characterization of CPT-11 hydrolysis by human
liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res.
60:1189–1192. 2000.PubMed/NCBI
|
|
103
|
Bencharit S, Morton CL, Howard-Williams
EL, Danks MK, Potter PM and Redinbo MR: Structural insights into
CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol.
9:337–342. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
104
|
Bodor N and Buchwald P: Soft drug design:
general principles and recent applications. Med Res Rev. 20:58–101.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Wadkins RM, Morton CL, Weeks JK, Oliver L,
Wierdl M, Danks MK and Potter PM: Structural constraints affect the
metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]
carbonyloxycamptothecin (CPT-11) by carboxylesterases. Mol
Pharmacol. 60:355–362. 2001.PubMed/NCBI
|
|
106
|
Wierdl M, Morton CL, Weeks JK, Danks MK,
Harris LC and Potter PM: Sensitization of human tumor cells to
CPT-11 via adenoviral-mediated delivery of a rabbit liver
carboxylesterase. Cancer Res. 61:5078–5082. 2001.PubMed/NCBI
|
|
107
|
Kojima A, Hackett NR, Ohwada A and Crystal
RG: In vivo human carboxylesterase cDNA gene transfer to activate
the prodrug CPT-11 for local treatment of solid tumors. J Clin
Invest. 101:1789–1796. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
van Dillen IJ, Mulder NH, Vaalburg W, de
Vries EF and Hospers GA: Influence of the bystander effect on
HSV-tk/GCV gene therapy. A review. Curr Gene Ther. 2:307–322.
2002.PubMed/NCBI
|
|
109
|
Gerolami R, Cardoso J, Lewin M, Bralet MP,
Sa Cunha A, Clement O, Brechot C and Tran PL: Evaluation of HSV-tk
gene therapy in a rat model of chemically induced hepatocellular
carcinoma by intratumoral and intrahepatic artery routes. Cancer
Res. 60:993–1001. 2000.PubMed/NCBI
|
|
110
|
Fillat C, Carrio M, Cascante A and Sangro
B: Suicide gene therapy mediated by the Herpes Simplex virus
thymidine kinase gene/Ganciclovir system: fifteen years of
application. Curr Gene Ther. 3:13–26. 2003.PubMed/NCBI
|
|
111
|
Huang Q, Pu P, Xia Z and You Y: Exogenous
wt-p53 enhances the antitumor effect of HSV-TK/GCV on C6 glioma
cells. J Neurooncol. 82:239–248. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Cowen RL, Williams JC, Emery S, Blakey D,
Darling JL, Lowenstein PR and Castro MG: Adenovirus vector-mediated
delivery of the prodrug-converting enzyme carboxypeptidase G2 in a
secreted or GPI-anchored form: High-level expression of this active
conditional cytotoxic enzyme at the plasma membrane. Cancer Gene
Ther. 9:897–907. 2002. View Article : Google Scholar
|
|
113
|
Muller FJ, Snyder EY and Loring JF: Gene
therapy: can neural stem cells deliver? Nat Rev Neurosci. 7:75–84.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Kim SU, Jeung EB, Kim YB, Cho MH and Choi
KC: Potential tumor-tropic effect of genetically engineered stem
cells expressing suicide enzymes to selectively target invasive
cancer in animal models. Anticancer Res. 31:1249–1258. 2011.
|
|
115
|
Tang Y, Shah K, Messerli SM, Snyder E,
Breakefield X and Weissleder R: In vivo tracking of neural
progenitor cell migration to glioblastomas. Hum Gene Ther.
14:1247–1254. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Power AT and Bell JC: Cell-based delivery
of oncolytic viruses: a new strategic alliance for a biological
strike against cancer. Mol Ther. 15:660–665. 2007.PubMed/NCBI
|
|
117
|
Kim KY, Yi BR, Lee HR, Kang NH, Jeung EB,
Kim SU and Choi KC: Stem cells with fused gene expression of
cytosine deaminase and interferon-β migrate to human gastric cancer
cells and result in synergistic growth inhibition for potential
therapeutic use. Int J Oncol. 40:1097–1104. 2012.PubMed/NCBI
|
|
118
|
Aboody KS, Najbauer J and Danks MK: Stem
and progenitor cell-mediated tumor selective gene therapy. Gene
Ther. 15:739–752. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Gutova M, Najbauer J, Frank RT, Kendall
SE, Gevorgyan A, Metz MZ, Guevorkian M, Edmiston M, Zhao D, Glackin
CA, et al: Urokinase plasminogen activator and urokinase
plasminogen activator receptor mediate human stem cell tropism to
malignant solid tumors. Stem Cells. 26:1406–1413. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Bithell A and Williams BP: Neural stem
cells and cell replacement therapy: making the right cells. Clin
Sci. 108:13–22. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Kim SK, Kim SU, Park IH, Bang JH, Aboody
KS, Wang KC, Cho BK, Kim M, Menon LG, Black PM and Carroll RS:
Human neural stem cells target experimental intracranial
medulloblastoma and deliver a therapeutic gene leading to tumor
regression. Clin Cancer Res. 12:5550–5556. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Sohur US, Emsley JG, Mitchell BD and
Macklis JD: Adult neurogenesis and cellular brain repair with
neural progenitors, precursors and stem cells. Philos Trans R Soc
Lond B Biol Sci. 361:1477–1497. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Kim SU, Park IH, Kim TH, Kim KS, Choi HB,
Hong SH, Bang JH, Lee MA, Joo IS, Lee CS and Kim YS: Brain
transplantation of human neural stem cells transduced with tyrosine
hydroxylase and GTP cyclohydrolase 1 provides functional
improvement in animal models of Parkinson disease. Neuropathology.
26:129–140. 2006. View Article : Google Scholar
|
|
124
|
Joo KM, Park IH, Shin JY, Jin J, Kang BG,
Kim MH, Lee SJ, Jo MY, Kim SU and Nam DH: Human neural stem cells
can target and deliver therapeutic genes to breast cancer brain
metastases. Mol Ther. 17:570–575. 2009. View Article : Google Scholar : PubMed/NCBI
|
